Integrative discovery of treatments for high-risk neuroblastoma
We lack effective treatment for half of children with high-risk neuroblastoma. Here, the authors introduce an algorithm that can predict the effect of interventions on gene expression signatures associated with high disease processes and risk, and identify and validate promising drug targets.
Guardado en:
Autores principales: | Elin Almstedt, Ramy Elgendy, Neda Hekmati, Emil Rosén, Caroline Wärn, Thale Kristin Olsen, Cecilia Dyberg, Milena Doroszko, Ida Larsson, Anders Sundström, Marie Arsenian Henriksson, Sven Påhlman, Daniel Bexell, Michael Vanlandewijck, Per Kogner, Rebecka Jörnsten, Cecilia Krona, Sven Nelander |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9eefbf3ff5bb4e6b9e9c8aacbd9a935c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
p53-Mediated Radiosensitization of <sup>177</sup>Lu-DOTATATE in Neuroblastoma Tumor Spheroids
por: Sara Lundsten, et al.
Publicado: (2021) -
Single-cell RNAseq and longitudinal proteomic analysis of a novel semi-spontaneous urothelial cancer model reveals tumor cell heterogeneity and pretumoral urine protein alterations.
por: Iliana K Kerzeli, et al.
Publicado: (2021) -
Neuroblastoma
por: Fuentes,Luis, et al.
Publicado: (1976) -
Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
por: Agnes Rasmuson, et al.
Publicado: (2012) -
Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance
por: Susanne Fransson, et al.
Publicado: (2020)